Terms: = Lung cancer AND TNFAIP3, TNFA1P2, 7128, ENSG00000118503, OTUD7C, MGC138687, MGC104522, A20, MGC138688, P21580 AND Treatment
26 results:
1. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
2. Identification of a novel RSRC1-ALK (R6: a20) fusion using next-generation sequencing technique.
Xia J; Chen S; Zhang Z; Wang J
Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
[TBL] [Abstract] [Full Text] [Related]
3. [Ceritinib as First-line treatment for Advanced lung Adenocarcinoma
with COX7A2L-ALK Fusion: A Case Report and Literature Review].
Yuan J; Pan R; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):319-324. PubMed ID: 37183647
[TBL] [Abstract] [Full Text] [Related]
4. lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract] [Full Text] [Related]
5. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract] [Full Text] [Related]
6. ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell lung cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.
Sánchez-Herrero E; Campos-Silva C; Cáceres-Martell Y; Robado de Lope L; Sanz-Moreno S; Serna-Blasco R; Rodríguez-Festa A; Ares Trotta D; Martín-Acosta P; Patiño C; Coronado MJ; Beneitez A; Jara R; Lago-Baameiro N; Camino T; Cruz-Bermúdez A; Pardo M; González-Rumayor V; Valés-Gómez M; Provencio M; Romero A
Clin Chem; 2022 May; 68(5):668-679. PubMed ID: 35348673
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
8. Down-regulation of a20 promotes immune escape of lung adenocarcinomas.
Breitenecker K; Homolya M; Luca AC; Lang V; Trenk C; Petroczi G; Mohrherr J; Horvath J; Moritsch S; Haas L; Kurnaeva M; Eferl R; Stoiber D; Moriggl R; Bilban M; Obenauf AC; Ferran C; Dome B; Laszlo V; Győrffy B; Dezso K; Moldvay J; Casanova E; Moll HP
Sci Transl Med; 2021 Jul; 13(601):. PubMed ID: 34233950
[TBL] [Abstract] [Full Text] [Related]
9. Discovery of a novel linc01125 isoform in serum exosomes as a promising biomarker for NSCLC diagnosis and survival assessment.
Xian J; Zeng Y; Chen S; Lu L; Liu L; Chen J; Rao B; Zhao Z; Liu J; Xie C; Zhu L; Zhang D; Qiu F; Lu J; Yang L
Carcinogenesis; 2021 Jun; 42(6):831-841. PubMed ID: 33928340
[TBL] [Abstract] [Full Text] [Related]
10. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract] [Full Text] [Related]
11. lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract] [Full Text] [Related]
12. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract] [Full Text] [Related]
13. A Family With a20 Haploinsufficiency Presenting With Novel Clinical Manifestations and Challenges for treatment.
Hautala T; Vähäsalo P; Kuismin O; Keskitalo S; Rajamäki K; Väänänen A; Simojoki M; Säily M; Pelkonen I; Tokola H; Mäkinen M; Kaarteenaho R; Jartti A; Hautala N; Kantola S; Jackson P; Glumoff V; Saarela J; Varjosalo M; Eklund KK; Seppänen MRJ
J Clin Rheumatol; 2021 Dec; 27(8):e583-e587. PubMed ID: 31977656
[TBL] [Abstract] [Full Text] [Related]
14. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract] [Full Text] [Related]
15. TNF-α-induced protein 3 is a key player in childhood asthma development and environment-mediated protection.
Krusche J; Twardziok M; Rehbach K; Böck A; Tsang MS; Schröder PC; Kumbrink J; Kirchner T; Xing Y; Riedler J; Dalphin JC; Pekkanen J; Lauener R; Roponen M; Li J; Wong CK; Wong GWK; Schaub B;
J Allergy Clin Immunol; 2019 Dec; 144(6):1684-1696.e12. PubMed ID: 31381928
[TBL] [Abstract] [Full Text] [Related]
16. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract] [Full Text] [Related]
17. CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK.
Liang C; Zhang N; Tan Q; Liu S; Luo R; Wang Y; Shi Y; Han X
Curr Cancer Drug Targets; 2019; 19(8):655-665. PubMed ID: 30381078
[TBL] [Abstract] [Full Text] [Related]
18. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract] [Full Text] [Related]
19. Next-generation sequencing facilitates detection of the classic E13-a20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.
Volckmar AL; Endris V; Bozorgmehr F; Lier C; Porcel C; Kirchner M; Leichsenring J; Penzel R; Thomas M; Schirmacher P; Warth A; Stenzinger A
Diagn Pathol; 2016 Nov; 11(1):133. PubMed ID: 27863497
[TBL] [Abstract] [Full Text] [Related]
20. miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell lung cancers.
Langsch S; Baumgartner U; Haemmig S; Schlup C; Schäfer SC; Berezowska S; Rieger G; Dorn P; Tschan MP; Vassella E
Cancer Res; 2016 Jul; 76(14):4160-9. PubMed ID: 27199349
[TBL] [Abstract] [Full Text] [Related]
[Next]
